Immunome Quarterly Cash Flow Statement
NASDAQ: IMNMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
19.55+0.24 (+1.24%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Immunome free cash flow
In the quarter ended Jun 30, 2026, Immunome generated -$61.7 million of operating cash flow and spent $2.2 million on capital expenditures. That left free cash flow of -$63.9 million.
Summary generated from market data by MetaCap's automated system. Methodology
Immunome cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -73.13M | -53.84M | -69.90M | -57.46M | -43.40M | -41.64M | -80.25M | -47.10M | -36.12M | -129.49M | -92.63M | -4.34M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 957.00K | 603.00K | 629.00K | 589.00K | 637.00K | 611.00K | 450.00K | 411.00K | 549.00K | 157.00K | 151.00K | 111.00K |
| Stock-Based Compensation | 8.80M | 7.95M | 7.89M | 6.75M | 5.35M | 5.70M | 5.47M | 4.89M | 3.23M | 2.16M | 2.88M | 1.08M |
| Change in Working Capital | -5.71M | -3.68M | -2.32M | 3.73M | -12.56M | -8.44M | 5.17M | -3.63M | -3.99M | 3.84M | -10.20M | -4.43M |
| Operating Cash Flow | -61.69M | -58.64M | -47.95M | -40.51M | -49.40M | -53.05M | -42.06M | -34.17M | -23.40M | -11.17M | -17.46M | -8.61M |
| Capital Expenditures | -2.18M | -3.00M | -4.00M | -1.12M | -905.00K | -3.67M | -1.13M | -1.54M | -2.34M | -2.16M | -349.00K | -36.00K |
| Investing Cash Flow | -304.35M | -12.02M | -4.00M | 123.88M | -64.17M | 5.09M | 9.76M | 24.10M | -81.69M | -37.23M | -30.00M | -36.00K |
| Financing Cash Flow | 1.06M | -135.00K | 432.80M | 45.39M | -55.00K | 162.23M | 20.09M | 305.00K | 694.00K | 219.44M | 55.50M | 60.88M |
| Net Change in Cash | -364.99M | -70.79M | 380.84M | 128.76M | -113.63M | 114.26M | -12.22M | -9.76M | -104.39M | 171.04M | 8.04M | 52.23M |
| Free Cash Flow | -63.87M | -61.64M | -51.95M | -41.63M | -50.31M | -56.72M | -43.19M | -35.71M | -25.74M | -13.33M | -17.81M | -8.65M |
This table shows 12 quarterly periods of Immunome's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow IMNM's reporting calendar. What is a cash flow statement?